EGFR 20ins Second-line Treatment Battlefield Rekindles: Can Savolitinib Break Through with Full-Scale Layout of Fumetinib? | New Drug Value Decoding

If you’re trading stocks, just look at Golden Qilin analysts’ research reports—authoritative, professional, timely, comprehensive—helping you uncover high-potential thematic opportunities!

The recommended level in the CSCO (Chinese Society of Clinical Oncology) guidelines is the bridge connecting high-level medical evidence with complex clinical decision-making. It’s not just a simple tiering system; it’s the result of a comprehensive consideration of evidence strength, drug accessibility, and expert consensus, directly determining what kinds of treatment plans clinicians will see in practice, and the priority level at which these plans are adopted.

CSCO guidelines categorize recommended levels mainly into three tiers. Tier I recommendations are the standard treatment options that, under current conditions, patients should prioritize the most; they represent well-established regimens with proven efficacy that most patients can afford and access. Tier II recommendations indicate high evidence strength but slightly worse accessibility, or slightly lower evidence strength but strong expert consensus. Tier III recommendations indicate relatively lower evidence strength, but regimens that are commonly used in clinical practice or have exploratory value, and that experts deem acceptable.

In the oncology diagnosis and treatment era led by evidence-based medicine, CSCO guidelines are not only a clinician’s pocket reference, but also a litmus test for assessing the value of innovative drugs. Recently, Eisai announced that the processing steps for the company’s drug registration application for furmonertinib tablets for EGFR exon 20 insertion mutation NSCLC second-line treatment indications—filed as “Furmonertinib (methanesulfonate) tablets EGFR exon 20 insertion mutation NSCLC second-line treatment indication”—have been updated to “Approved—pending issuance of certificate.” We break down the diagnostic and treatment pathway based on the CSCO guidelines, and attempt to analyze the future clinical positioning of this drug for this indication, its potential for market access, and how it can carve out a path to stand out in market competition.

EGFR exon 20 insertion mutations are a common subtype among EGFR mutations in non-small cell lung cancer (NSCLC). In China, they account for about 2%-5% of NSCLC patients with EGFR mutations. Compared with patients carrying common EGFR mutations, patients with EGFR exon 20 insertion mutations typically have worse prognosis.

Specifically, compared with patients carrying common EGFR mutations, patients with EGFR exon 20 insertion mutations have a 75% higher risk of death. The former’s median overall survival (mOS) is 16.2 months, while the latter can reach 25.5 months.

At the same time, patients with EGFR exon 20 insertion mutations have a 93% higher risk of disease progression or death. This is reflected in a median progression-free survival (mPFS) of only 5.1 months, whereas the mPFS for patients with common EGFR mutations is 10.3 months.

For late-stage/metastatic NSCLC patients with EGFR exon 20 insertion mutations, the “China Clinical Oncology Society Non-Small Cell Lung Cancer Diagnosis and Treatment Guideline 2025” states that evmonotumab combined with chemotherapy is a Tier I recommended first-line treatment regimen. In the phase II, single-arm registration WUKONG6 clinical study in China, treatment with shovitinib (suvotinib) for EGFR exon 20 insertion mutation achieved an ORR of 61% in the overall population. Based on this, the NMPA has approved its use for locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutations who have experienced disease progression after prior platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and it has been included as a Tier I recommended option.

In addition, for this indication, the Tier II recommendations are all second-line (and later-line) treatment options referencing regimens for non-driver-gene NSCLC, and the available treatment choices are relatively limited. The furmonertinib that Eisai focuses on is also for second-line treatment of NSCLC with EGFR exon 20 insertion mutations, and it will directly compete with suvinotinig.

Data show that phase II clinical study results for furmonertinib in EGFR exon 20 insertion mutation, previously treated NSCLC patients indicate that the confirmed objective response rate (ORR) is 44.3%, median progression-free survival (mPFS) is 8.3 months, and median overall survival (OS) is 22.9 months.

Looking at indirect head-to-head comparisons, the ORR for suvinotinig in second-line treatment is 61%, higher than furmonertinib’s; the median progression-free survival is 6.5 months, lower than furmonertinib’s. From the available data, furmonertinib demonstrates robust efficacy in previously treated patients with EGFR exon 20 insertion mutations, especially showing a potential trend superior to suvinotinig in terms of progression-free survival.

Although the objective response rate is slightly lower than suvinotinig’s, its longer median progression-free survival and a median overall survival of nearly two years suggest that the drug has differentiated advantages in controlling disease progression and extending survival, and it may form a complementary positioning in clinical practice. However, the current data still come from a phase II, single-arm study with a limited sample size and no control group. If its survival benefit cannot be validated through larger-scale confirmatory studies afterward, the recommended tier of furmonertinib in the CSCO guidelines may be constrained.

From the competitive landscape perspective, the second-line treatment field for EGFR exon 20 insertion mutations is currently dominated by suvinotinig. More importantly, on March 22, Dizhe Pharmaceutical released an announcement stating that the phase III clinical trial of suvinotinig for first-line treatment of EGFR exon20ins non-small cell lung cancer has yielded positive results. The indication is expected to expand to first-line treatment, further consolidating its full-range layout advantage in the EGFR exon 20 insertion mutation domain.

Additionally, in terms of the overall market scale, EGFR exon 20 insertion mutations account for only 2%-5% of EGFR-mutated NSCLC, meaning the overall patient base is relatively small. Therefore, if the furmonertinib indication is limited to second-line treatment, the patient population would be further narrowed, the commercialization ceiling would be lower, and it may be difficult for it to become the company’s core growth engine.

A massive amount of news and precise interpretation—right on Sina Finance APP

责任编辑：公司观察